Bristol Myers SquibbBMYRevenue: is the business selling more than it used to?
$48.2B−0% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $48.2B in 2025, compounding +1% a year since 2022 though the path has been bumpy. The trailing twelve months are already running at $49.2B, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYNet income: how much of that revenue becomes profit?
$7.1BFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $7.1B in 2025, compounding +4% a year over three years. Earnings per share moved +84% over the last twelve months. Trailing twelve-month profit stands at $9.3B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYHow fast is it growing, year by year?
-0.2%revenue growth, FY 2025
Off the axis: 2018 earnings +388.6% · 2020 earnings -362.1% · 2024 earnings -211.5% - rebounds off a collapsed prior year.
→Revenue grew -0% in 2025 against a five-year average of +3%. 2018's +389% earnings rebound off a collapsed base and 2020's swing into loss (-362%) and 2024's swing into loss (-212%) sits off the axis.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYRevenue per share: is your slice growing as fast as the company?
$23.64revenue per share, FY 2025
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Revenue per share reached $23.64 in 2025, compounding +3% a year against +1% for BMY as a whole. Buybacks added roughly 1.7 points to your per-share result. Free cash flow per share stands at $6.30.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYFree cash flow: what is left in real cash after everything?
$12.8B−8% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $12.8B in 2025, compounding +2% a year since 2022. The trailing twelve months stand at $11.4B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYHow much of every sales dollar ends up as free cash?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→27 cents of every sales dollar became free cash in 2025, and it has held steady since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYWhat does staying competitive cost, per dollar of sales?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The biggest claim on each sales dollar is research and development, at 21% of revenue (capital spending 3%, stock compensation 1%).
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYMargins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Net margin stands at 15% in 2025. BMY doesn't break out gross or operating margin in its filings, so net is the only layer the data supports.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYWhat does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→BMY earns 42% on shareholders' capital. Return on capital employed isn't meaningful for this business model, so ROE carries the picture alone.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYWhat has the market paid for BMY over time?
14.7xP/E today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 14.7x earnings, the market is paying 12% less than BMY's own 9-year median of 16.7x. Pessimism is priced in - the question is whether it is deserved.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYWhat cash return does the business throw off per dollar of market value?
8.4%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 8.4% of annual free cash flow, less than its 11-year median of 11.2% - you are paying up for the same cash.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYCould it handle its debt if things went wrong?
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end
→Debt of $43.1B sits against $8.7B of cash, or 1.9x shareholders' equity.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYIs the company's own capital growing?
→The company's own capital shrank from $29.4B in 2023 to $22.3B (-24%). Buybacks or losses are drawing the buffer down - the distinction matters.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYHow much goes back, and how much leaks out as stock comp?
→Shareholders received $5.0B in dividends in 2025. Stock compensation issued $553M of new shares in the same year, offsetting 11% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYHow fast is your ownership being diluted - or concentrated?
→The share count grew 0.6% in 2025. Your slice of the company shrinks by that much each year unless earnings grow faster.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYIs the dividend cheque growing?
→The dividend per share reached $2.47 in 2025, compounding +7% a year since 2020.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYCan it afford the dividend?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The dividend consumed 72% of profit and 39% of free cash flow in 2025. That leaves room to keep paying through a weak year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYBMY has issued or retired shares - did shareholders end up better off?
→BMY issued +19% more shares from 2011 to 2025, but revenue per share still rose +91%. The dilution bought more growth than it cost existing holders.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Bristol Myers SquibbBMYAre the people running it buying or selling?
→Insiders sold $2M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 57 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30